Foamix Pharmaceuticals (NASDAQ:FOMX) PT Set at $12.00 by HC Wainwright

Foamix Pharmaceuticals (NASDAQ:FOMX) has been given a $12.00 price target by stock analysts at HC Wainwright in a research report issued on Friday, January 5th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 79.10% from the company’s current price.

A number of other analysts have also weighed in on FOMX. Guggenheim reissued a “buy” rating and issued a $8.00 price target on shares of Foamix Pharmaceuticals in a report on Thursday, December 14th. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th.

Shares of Foamix Pharmaceuticals (FOMX) traded up $0.12 on Friday, reaching $6.70. 132,562 shares of the company’s stock were exchanged, compared to its average volume of 87,974. The company has a market capitalization of $250.80, a PE ratio of -5.11 and a beta of 1.62. Foamix Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $11.11.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.90 million. During the same quarter last year, the firm posted ($0.19) EPS. The business’s revenue was down 64.6% on a year-over-year basis. research analysts predict that Foamix Pharmaceuticals will post -1.35 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXA grew its holdings in Foamix Pharmaceuticals by 14.1% during the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock worth $4,374,000 after acquiring an additional 116,298 shares during the period. DAFNA Capital Management LLC grew its holdings in Foamix Pharmaceuticals by 9.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after acquiring an additional 30,000 shares during the period. Bank of New York Mellon Corp grew its holdings in Foamix Pharmaceuticals by 38.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after acquiring an additional 151,849 shares during the period. PDT Partners LLC acquired a new stake in Foamix Pharmaceuticals during the 2nd quarter worth $304,000. Finally, UBS Asset Management Americas Inc. grew its holdings in shares of Foamix Pharmaceuticals by 1.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock valued at $493,000 after buying an additional 1,633 shares during the period. 57.43% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/foamix-pharmaceuticals-fomx-given-a-12-00-price-target-by-hc-wainwright-analysts.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply